Third phase III trial of netupitant/palonosetron for the prevention of chemotherapy-induced nausea and vomiting.
Phase of Trial: Phase III
Latest Information Update: 30 May 2013
At a glance
- Drugs Netupitant/palonosetron (Primary)
- Indications Chemotherapy-induced nausea and vomiting
- Focus Registrational; Therapeutic Use
- Sponsors Helsinn Healthcare SA
- 30 May 2013 Status changed from not yet recruiting to unconfirmed; it is not known if this trial was commenced.
- 27 Sep 2011 New trial record